Benzinga | Sep 1, 2020 05:13AM EDT

Needham Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $91

Needham analyst Chad Messer maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $89 to $91.